Drug
Radium Ra 223 dichloride clinical trials
Also written Xofigo and Radium-223 dichloride.
A product of Radium; its studies count on that page too.
How studies write it
Studies that test it under each name
Studies by the year they started
35 studies that test it; most in 2014 (6)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 6 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 23 · Other 12
Bayer (22) · M.D. Anderson Cancer Center (3) · University of Utah (2) · Icahn School of Medicine at Mount Sinai (1) · Massachusetts General Hospital (1) · Sir Mortimer B. Davis - Jewish General Hospital (1) · Angela Taber MD (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
Abiraterone Acetate (1) · Abiraterone (1) · Prednisone (1) · Cabazitaxel (1) · Carboplatin (1) · Enzalutamide (1) · Denosumab (1) · Hormone Therapy (1)
Studies
Open first, then newest update. How each study uses radium Ra 223 dichloride is read from its arms, and is right about nine times in ten.
Testing it · 35
- RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Active, not recruitingPhase 4BayerNCT04597125Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesCompletedPhase 3BayerNCT00699751Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the BonesCompletedPhase 1BayerNCT04521361Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to BoneCompletedPhase 2University of UtahNCT03304418Written as Radium Ra 223 Dichloride
- Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsCompletedPhase 3BayerNCT02043678Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedPhase 1BayerNCT03996473Written as Radium-223 dichloride (Xofigo, BAY 88-8223)
- Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)CompletedPhase 2Icahn School of Medicine at Mount SinaiNCT02903160Written as Radium-223 dichloride
- Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerCompletedPhase 2BayerNCT02258451Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- BAY88-8223, Dose Finding Study in Patients With HRPCCompletedPhase 2BayerNCT00337155Written as Radium-223 dichloride (BAY88-8223)
- BAY88-8223, Does Response Study in HRPC PatientsCompletedPhase 2BayerNCT00667199Written as Radium-223 dichloride (BAY88-8223)
- A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate CancerCompletedPhase 2Massachusetts General HospitalNCT02346526Written as Radium-223 dichloride
- Radium 223 in Castrate Resistant Prostate Cancer Bone MetastasesCompletedNot applicableM.D. Anderson Cancer CenterNCT02135484Written as Alpharadin
- Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT02366130Written as Ra-223 dichloride
- Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 TherapyCompletedPhase 2Sir Mortimer B. Davis - Jewish General HospitalNCT03062254Written as radium-223 dichloride
- Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in OsteosarcomaCompletedPhase 1/2M.D. Anderson Cancer CenterNCT01833520Written as Ra-223 Dichloride
- BrUOG L301 With Non-Small Cell Lung Cancer and Bone MetastasesCompletedPhase 2Angela Taber MDNCT02283749Written as Xofigo
- Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate CancerCompletedPhase 2University of UtahNCT02199197Written as Radium Ra 223 Dichloride
- Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerTerminatedPhase 2BayerNCT02258464Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- Study Testing Radium-223 Dichloride in Relapsed Multiple MyelomaTerminatedPhase 1/2BayerNCT02928029Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedPhase 1Hoffmann-La RocheNCT02814669Written as Radium-223 Dichloride
See all 35 studies that test radium Ra 223 dichloride →
Given in every arm · 2 — radium Ra 223 dichloride is usual care beside what is tested
- A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)CompletedPhase 2BayerNCT02034552Written as Radium-223 dichloride (Xofigo, BAY88-8223)
- A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)CompletedPhase 1/2BayerNCT01106352Written as Radium-223 dichloride (Xofigo, BAY88-8223)
As the comparator · 2 — what is tested is compared with radium Ra 223 dichloride
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Radium Chloride Ra-223
- Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal TherapyStatus unknownPhase 3Amsterdam UMC, location VUmcNCT03458559Written as Radium-223 chloride
Codes
What other systems call radium Ra 223 dichloride · ClinicalTrials.gg INT006278
- MeSH (NLM) C581106radium Ra 223 dichlorideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RJ00KV3VTGRADIUM RA-223 DICHLORIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1424174Confirmed FDA, Wikidata
- Wikidata Q4735269radium ra-223 dichlorideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C62535Radium Ra 223 DichlorideConfirmed FDA, Wikidata
- DrugBank DB08913One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C581106 | radium Ra 223 dichloride | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RJ00KV3VTG | RADIUM RA-223 DICHLORIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1424174 | — | Confirmed FDA, Wikidata |
| Wikidata | Q4735269 | radium ra-223 dichloride | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C62535 | Radium Ra 223 Dichloride | Confirmed FDA, Wikidata |
| DrugBank | DB08913 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.